

Regd. Office :
'Zydus Tower',
Satellite Cross Roads,
Ahmedabad 380 015. India.
Phone : +91-79-2686 8100 (20 Lines)
Fax : +91-79-2686 2368
www.zyduscadila.com
CIN:L24230GJ1995PLC025878

August 11, 2017

Listing Department
BOMBAY STOCK EXCHANGE LIMITED
P J Towers, Dalal Street, Fort,
Mumbai-400 001

Code: 532 321

Listing Department
NATIONAL STOCK EXCHANGE OF INDIA LIMITED
Exchange Plaza, Bandra Kurla Complex,
Bandra (E),
Mumbai-400 051

Code: CADILAHC

Re: **Unaudited Financial Results for the quarter ended on June 30, 2017**

Dear Sir,

Please find attached herewith the unaudited financial results for the quarter ended on June 30, 2017, reviewed by the Audit Committee and taken on record by the Board of Directors today i.e. August 11, 2017 pursuant to Regulation No. 33[2][a] of the SEBI [Listing Obligations and Disclosure Requirements] Regulations, 2015.

Please receive the same in order.

Thanking you,

Yours faithfully,
For, **CADILA HEALTHCARE LIMITED**



UPEN H. SHAH
COMPANY SECRETARY

Encl.: As above

Statement of Results for the Quarter Ended 30/06/2017

Rupees in Millions				Rupees in Millions					
CONSOLIDATED				COMPANY					
3 Months ended 30/06/2017 (Unaudited)	Preceding 3 months ended 31/03/2017 (Audited)	Corresponding 3 months ended 30/06/2016 in the previous year (Unaudited)	Previous year ended 31/03/2017 (Audited)	Sr. No.	Particulars	3 Months ended 30/06/2017 (Unaudited)	Preceding 3 months ended 31/03/2017 (Audited)	Corresponding 3 months ended 30/06/2016 in the previous year (Unaudited)	Previous year ended 31/03/2017 (Audited)
21,672	24,642	22,624	94,156	1	Revenue	10,004	7,666	8,750	30,980
616	607	707	2,097	a	Revenue from operations	550	619	577	1,765
22,288	25,249	23,331	96,253	i	Sales	10,554	8,285	9,327	32,745
210	731	153	1,286	ii	Other operating income	520	4,046	435	5,831
22,498	25,980	23,484	97,539	iii	Total revenue from operations	11,074	12,331	9,762	38,576
5,263	5,454	4,333	18,310	b	Other income	3,033	2,767	2,329	9,267
5,066	4,382	3,071	17,529	c	Expenses	887	266	619	2,288
(2,035)	(552)	337	(1,388)	d	Cost of materials consumed	(861)	(305)	(112)	(1,470)
315	467	460	1,958	e	Purchases of stock-in-trade	127	83	92	438
4,288	4,005	3,572	15,002	f	Changes in inventories of finished goods, work-in-progress and stock-in-trade	1,775	1,565	1,485	6,208
219	99	140	450	g	Excise Duty on Sales	119	(38)	56	111
1,220	1,145	843	3,750	h	Employee benefits expense	664	545	590	2,509
6,618	6,857	6,319	25,806	i	Finance costs	3,609	3,300	3,083	12,803
20,954	21,857	19,075	81,417	j	Depreciation and amortisation expense	9,353	8,183	8,142	32,154
1,544	4,123	4,409	16,122	k	Other expenses	1,721	4,148	1,620	6,422
0	0	2	3	l	Total expenses	0	0	0	0
1,544	4,123	4,407	16,119	m	Profit before exceptional items, tax and share of profit/ [loss] of joint ventures (1-2)	1,721	4,148	1,620	6,422
763	1,203	373	1,918	n	Exceptional items	355	270	316	594
(470)	(1,184)	171	(629)	o	Tax expense	452	(836)	0	(791)
293	19	544	1,289	p	Current tax	807	(566)	316	(197)
1,251	4,104	3,863	14,830	q	Deferred tax	914	4,714	1,304	6,619
202	(179)	182	338	r	Total tax	0	0	0	0
1,453	3,925	4,045	15,168	s	Profit before share of profit/ [loss] of joint ventures (5-6)	914	4,714	1,304	6,619
69	70	61	291	t	Share of profit/ [loss] of joint ventures (net of tax)	0	0	0	0
1,384	3,855	3,984	14,877	u	Net Profit for the year before Non-Controlling Interests (7+8)	914	4,714	1,304	6,619
				v	Non-Controlling Interests	0	0	0	0
				w	Net Profit after taxes, Non-Controlling Interests and share of profit/ [loss] of joint ventures (9-10)	914	4,714	1,304	6,619
				x	Other Comprehensive Income (OCI)				
(53)	(122)	(11)	(212)	a	Items that will not be reclassified to profit or loss:	(25)	(13)	(30)	(103)
248	163	0	147	i	Re-measurement gains/ (losses) on post employment defined benefit plans	248	159	9	138
5	15	0	45	ii	Net Gain/ (Loss) on Fair Value through OCI Equity Securities	5	(8)	10	22
200	56	(11)	(20)	iii	Income tax effect on above items	228	138	(11)	57
				iv	Total				
216	256	0	75	b	Items that will be reclassified to profit or loss:	0	0	0	0
0	0	0	75	i	Exchange differences on translation of foreign operations	0	0	0	0
216	256	0	75	ii	Income tax effect on above items	0	0	0	0
0	(4)	0	(4)	iii	Total	0	0	0	0
416	308	(11)	51	c	Share of OCI of joint ventures (net of tax)	0	0	0	0
1,869	4,233	4,034	15,219	d	Other Comprehensive Income for the year, net of tax	228	138	(11)	57
1,800	4,163	3,973	14,928	e	Total Comprehensive Income (9+12)	1,142	4,852	1,293	6,676
69	70	61	291	f	Owners of the Parent	1,142	4,852	1,293	6,676
1,024	1,024	1,024	1,024	g	Non-Controlling Interests	0	0	0	0
				h	Total Comprehensive Income for the year attributable to:	1,024	1,024	1,024	1,024
1,35	3,77	3,89	14,53	i	Paid-up equity share capital (Face value Re. 1/-)	0.89	4.61	1.27	6.47
1,35	3,77	3,89	14,53	j	Reserves excluding Retention Reserve as per balance sheet of previous accounting year (i.e. Other Equity)	0.89	4.61	1.27	6.47
				k	Earnings per share (not annualised)				
				l	Basic (Rs.)				
				m	Diluted (Rs.)				

Notes :

- [1] The above results for the quarter ended June 30, 2017 were reviewed by the Audit Committee and then approved by the Board of Directors at their meeting held on August 11, 2017.
- [2] The Statutory Auditors of the Company have carried out a "Limited Review" of the above results as per Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015.
- [3] The Scheme of Amalgamation between Zyclus Healthcare Limited [ZHL] and Biochem Pharmaceutical Industries Limited [Biochem] [Scheme-1], 100% subsidiaries of the Company, was approved by the Hon'ble National Company Law Tribunal, Ahmedabad Bench [NCLT] vide its order dated March 15, 2017 and has been made effective from March 27, 2016. The Scheme-1 entails Amalgamation of Biochem with ZHL from appointed date of March 31, 2016. Corresponding figures for the quarter ended June 30, 2016 have been recast/ regrouped to give effect of the Scheme-1.
- [4] The Scheme of Arrangement between the Company and ZHL, a 100% subsidiary of the Company and their respective shareholders and creditors [Scheme-2] was sanctioned by NCLT vide its order dated May 18, 2017. The Scheme-2 entails transfer of the India Human Formulations Undertaking [IHFU] of the Company which was transferred to and vested in ZHL on a going concern basis by way of a Stump Sale for a lump sum cash consideration from its appointed date of April 1, 2016. The Scheme-2 was made effective from May 19, 2017. Pursuant to the Scheme-2, the Company has transferred assets and liabilities pertaining to IHFU at their respective carrying value as at April 1, 2016. Corresponding figures for the quarter ended June 30, 2016 have been recast/ regrouped to give effect of the Scheme-2.
- [5] Exceptional items in the consolidated results include:

No.	Particulars	Rupees in Millions			
		3 Months ended 30/06/2017 (Unaudited)	Preceding 3 months ended 31/03/2017 (Audited)	Corresponding 3 months ended 30/06/2016 in the previous year (Unaudited)	Previous year ended 31/03/2017 (Audited)
a	Provision for various expenses related to the closure of business operations in Japan	0	0	2	3

[6] Figures of previous reporting periods have been regrouped/ reclassified wherever necessary to correspond with the figures of the current reporting period.

[7] The Company has one segment of activity viz., "Pharmaceuticals".

Ahmedabad, August 11, 2017

By Order of the Board,
For Cadila Healthcare Limited,



Pankaj R. Patel
Chairman